Literature DB >> 19078047

Outcomes for lumbar stenosis.

R L Swezey1.   

Abstract

To document the natural history and outcomes of lumbar spinal stenosis in patients with neurogenic claudication, 47 patients who had been evaluated 5 years earlier were evaluated by telephone interview. Thirty-one were reexamined. The average duration of symptoms was 8 years. All patients had bilateral lower extremity symptoms, which were more pronounced unilaterally in three patients.Of the nonsurgically treated cases, 43% (20/47) improved; 30% (14/47) were unchanged. Seven of 11 patients treated with intermittent traction 1-2 times weekly improved walking tolerance and reported less back pain. Eight of 13 improved their walking tolerance after 1-3 epidural cortico-steroid injections. The 23% (11/47) who did not improve or worsened reported improvement after laminectomy.The majority of patients with symptomatic spinal stenosis will stabilize or improve without surgery. For those with intolerable symptoms, laminectomy can usually provide appreciable symptomatic relief.

Entities:  

Year:  1996        PMID: 19078047     DOI: 10.1097/00124743-199606000-00004

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  3 in total

1.  Effects of transforaminal injection for degenerative lumbar scoliosis combined with spinal stenosis.

Authors:  Hee-Seung Nam; Yong Bum Park
Journal:  Ann Rehabil Med       Date:  2011-08-31

2.  Prospective one-year follow-up of lumbar spinal stenosis in a regional community.

Authors:  Koji Otani; Shin-Ichi Kikuchi; Shoji Yabuki; Akira Onda; Takuya Nikaido; Kazuyuki Watanabe; Shin-Ichi Konno
Journal:  J Pain Res       Date:  2018-03-02       Impact factor: 3.133

3.  The factors of deterioration in long-term clinical course of lumbar spinal canal stenosis after successful conservative treatment.

Authors:  Masanori Tsubosaka; Shuichi Kaneyama; Tomonori Yano; Koichi Kasahara; Aritetsu Kanemura; Masato Takabatake; Hiroaki Hirata; Masatoshi Sumi
Journal:  J Orthop Surg Res       Date:  2018-09-18       Impact factor: 2.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.